Clin2
NCT06297590Worth exploringRecruiting

First human study of a new Alzheimer's drug

Alzheimer Disease

Part of Brain & nervous system, Mental health clinical trials.

This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
48 people
Ages
50 years to 85 years
Study type
Interventional

Who can take part

  • You have mild to early Alzheimer's symptoms (memory changes for at least 6 months) and a diagnosis of early symptomatic Alzheimer's disease.
  • You have a study partner (someone who knows you well) who can spend at least 10 hours a week with you and come to appointments.
  • You are willing to have a PET scan that checks for tau protein in your brain (a sign of Alzheimer's).
  • You have not had previous treatments targeting tau protein or certain other Alzheimer's therapies in the past year.
  • You are generally healthy and do not have serious or unstable medical conditions like heart, liver, or kidney problems.
  • You are not pregnant, breastfeeding, or planning to become pregnant, and if male, you agree to use contraception.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07598370Recruiting· Phase 1
Testing LY3439539 for early-stage Alzheimer's disease

This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.

Irvine, California
NCT06657768Recruiting· Phase 1
Study of LY4006895 for healthy people and those with early Alzheimer's

This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.

Los Alamitos, California
NCT07787169Not yet recruiting· Phase 1
Amyloid-targeting therapy study for Alzheimer's disease and healthy participants

This study tests new treatments that target amyloid plaques in the brain, which are linked to Alzheimer's disease. It includes both healthy people and those with mild cognitive impairment or mild-to-moderate Alzheimer's, to see if the treatments are safe and how they affect the body.

Irvine, California
NCT05457998Enrolling by invitation
Study of Alzheimer’s brain markers using memory testing

This trial looks for signs of Alzheimer’s disease in the brain by using memory and thinking tests, and related study procedures. It may help researchers find better ways to identify Alzheimer’s-related changes earlier.

Providence, Rhode Island
NCT07787182Not yet recruiting· Phase 1
Study of LY4405094 in healthy people and people with Alzheimer's disease

This study tests a new drug called LY4405094 in healthy people and people with Alzheimer's disease. It aims to see if the drug is safe and how it works, but people with certain allergies (especially to adhesives) cannot join.

Irvine, California
NCT06957418Recruiting· Phase 2
Alzheimer's tau drug study for early stage patients

This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.

San Francisco, California

Hear when a new Alzheimer Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.